Bain buys 340-year-old pharma company to fast-track Japan’s drug development
Private equity firm expects $3.3bn acquisition of Tanabe will get boost from eased approval process for new medicine
Private equity firm expects $3.3bn acquisition of Tanabe will get boost from eased approval process for new medicine
